Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes

BMC Infectious Diseases
Ricky Hsu1, Jennifer S Fusco2, Cassidy Henegar3, Vani Vannappagari3, Andrew Clark4, Laurence Brunet2, Philip C. Lackey5, Gerald Pierone6, Gregory Fusco2
1NYU Langone Health Center, New York, NY, USA
2Epividian, Inc., Raleigh, NC, USA
3ViiV Healthcare, Durham, NC, USA
4ViiV Healthcare, Brentford Middlesex, UK
5Wake Forest School of Medicine, Winston-Salem, NC, USA
6Whole Family Health Center, Vero Beach, FL, USA

Tóm tắt

Abstract Background Multi-class resistance, intolerance, and drug–drug interactions can result in unique antiretroviral (ART) combinations for heavily treatment-experienced (HTE) people living with HIV (PLWH). We aimed to compare clinical outcomes between HTE and non-HTE PLWH. Methods Eligible ART-experienced PLWH in care in the OPERA® Cohort were identified in a cross-sectional manner on December 31, 2016 and observed from the date of initiation of the ART regimen taken on December 31, 2016 until loss to follow up, death, study end (December 31, 2018), or becoming HTE (non-HTE group only). In the absence of resistance data, HTE was defined based on the ART regimens used (i.e., exposed to ≥ 3 core agent classes or regimen suggestive of HTE). Time to virologic undetectability, failure, and immunologic preservation were assessed using Kaplan–Meier methods; cumulative probabilities were compared between the two groups. Regimen changes, incident morbidities, and death were described. Results A total of 24,183 PLWH (2277 HTE PLWH, 21,906 non-HTE) were followed for a median of 28 months (IQR 21, 38). Viremic HTE PLWH (viral load [VL] ≥ 50 copies/mL) were less likely to achieve undetectability (VL < 50 copies/mL; 24-month cumulative probability: 80% [95% Confidence Interval 77–82]) than their non-HTE counterparts (85% [84–86]). No difference was observed in the probability of maintaining VLs < 200 copies/mL over the first 48 months after achieving suppression (< 50 copies/mL). HTE PLWH were less likely than non-HTE PLWH to maintain CD4 cell counts ≥ 200 cells/µL (24-month cumulative probability: 95% HTE [91–93]; 97% non-HTE [97–97]), and more likely to change regimens (45% HTE; 41% non-HTE). Incident non-AIDS defining event (ADE) morbidities were common in both populations, though more likely among HTE PLWH (45%) than non-HTE PLWH (35%). Incident ADE morbidities and deaths were uncommon among HTE (ADEs 5%; deaths 2%) and non-HTE (ADEs 2%; deaths 1%) PLWH. Conclusions HTE PLWH were at greater risk of unfavorable treatment outcomes than non-HTE PLWH, suggesting additional therapeutic options are needed for this vulnerable population.

Từ khóa


Tài liệu tham khảo

Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492–500.

Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489–96.

WHO Expert Consultation. ART failure and strategies for switching ART regimens in the WHO European region. Copenhagen. 2007.

Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, Quinn JB, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retrovir. 2007;23(8):988–95.

Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400–14.

Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1-25.

Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis. 2006;6(8):496–507.

Henegar C, Vannappagari V, Viswanathan S, DeKoven M, Clark A, Ackerman P, et al. Identifying heavily treatment-experienced patients in a large administrative claims database. In: International AIDS Society (IAS) conference on HIV science in Mexico City, Mexico, July 21–24, 2019. 2019.

Hsu R, Henegar C, Fusco J, Vannappagari V, Llamoso C, Lackey P, et al. Identifying heavily treatment-experienced patients in the OPERA Cohort [Poster THPEB044]. In: 22nd international AIDS conference, Amsterdam, the Netherlands. 2018.

Pelchen-Matthews A, Borges AH, Reekie J, Rasmussen LD, Wiese L, Weber J, et al. Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort. J Acquir Immune Defic Syndr. 2021;87(2):806–17.

Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 2008;61(3):705–13.

Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS. 2005;19(10):1081–9.

Smith CJ, Phillips AN, Dauer B, Johnson MA, Lampe FC, Youle MS, et al. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med. 2009;10(1):19–27.

Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175–85.

Khanna N, Klimkait T, Schiffer V, Irigoyen J, Telenti A, Hirschel B, et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. AIDS. 2000;14(7):791–9.

Imaz A, Falco V, Ribera E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Rev. 2011;13(3):180–93.

Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, et al. The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study. PLoS ONE. 2014;9(3): e92606.

Benzie AA, Bansi LK, Fau-Sabin CA, Portsmouth S, Fau-Hill T, Johnson M, Fau-Gilson R, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS. 2007;21(11):1423–30.

Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004;190(11):1947–56.

Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740–51.

Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645–54.

Molina JM, Segal-Maurer S, Stellbrink HJ, Castagna A, Berhe M, Richmond GJ, et al. Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study). J Int AIDS Soc. 2021;24(S4): e25755.

Potard V, Goujard C, Valantin MA, Lacombe JM, Lahoulou R, Cheret A, et al. Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. BMC Infect Dis. 2018;18(1):326.

Colin X, Lafuma A, Costagliola D, Lang JM, Guillon P. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France. PharmacoEconomics. 2010;28(Suppl 1):59–68.

Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2014–2018. 2020 [updated May 2020]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Thông tin
Thông tin xuất bản

BMC Infectious Diseases

Thông tin tác giả